Neurocrine Biosciences secures $1B revolving credit facility
What's the deal? Neurocrine Biosciences, a San Diego-based biopharmaceutical company, has secured a $1 billion revolving credit facility with JPMorgan Chase Bank serving as lead arranger. Law firm Simpson Thacher represented JPMorgan in the transaction.
The revolving credit facility gives Neurocrine flexible access to up to $1 billion in capital, which it can draw on as needed rather than taking the full sum upfront.
Why now? Biotech and pharma companies have been locking in large credit facilities as the sector faces both growing capital needs and uncertain market conditions. A revolving facility of this size signals Neurocrine's confidence in its revenue trajectory — and lenders' confidence in its creditworthiness.
What could go wrong? Revolving credit facilities carry interest rate risk, especially if borrowing costs rise. Neurocrine also faces the usual pharma headwinds: regulatory setbacks, patent cliffs, and competitive pressure could affect its ability to service the debt.
The signal: Large credit facilities for mid-cap biopharma firms reflect a broader trend of the sector leaning on debt instruments — not just equity — to fund operations and acquisitions. JPMorgan's willingness to lead a $1 billion facility underscores strong institutional appetite for life sciences lending.
Read more: stblaw.com
